Molecular Partners AG (NASDAQ:MOLN - Get Free Report)'s share price dropped 0.6% during trading on Tuesday . The company traded as low as $5.36 and last traded at $5.36. Approximately 6,640 shares traded hands during mid-day trading, a decline of 12% from the average daily volume of 7,505 shares. The stock had previously closed at $5.39.
Wall Street Analysts Forecast Growth
Separately, Leerink Partnrs raised Molecular Partners to a "strong-buy" rating in a research note on Monday, October 7th.
View Our Latest Stock Report on Molecular Partners
Molecular Partners Stock Performance
The firm has a market cap of $233.30 million, a PE ratio of -2.69 and a beta of 1.05. The company's 50-day simple moving average is $5.44 and its two-hundred day simple moving average is $5.75.
Molecular Partners Company Profile
(
Get Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Further Reading
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
